Last reviewed · How we verify
NCT06926023
1550nm Non-ablative Fractional Vs 1927nm Thulium Fractional Laser for the Treatment of Female Pattern Hair Loss
NA trial testing 1550nm non-ablative fractional laser in Female Pattern Baldness in 10 participants. Not yet recruiting.
30 November 2025
Quick facts
| Lead sponsor | Goldman, Butterwick, Fitzpatrick and Groff |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 1 May 2025 |
| Primary completion | 30 November 2025 |
| Estimated completion | 31 December 2025 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 1550nm non-ablative fractional laser
- 1927 thulium fractional laser
Conditions studied
- Female Pattern Baldness — all drugs for Female Pattern Baldness →
Sponsor
Goldman, Butterwick, Fitzpatrick and Groff — full company profile →
Who can join
Adults 35 to 65, female only, with Female Pattern Baldness. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To evaluate the efficacy of either a 1550nm non-ablative fractional laser or a 1927nm thulium fractional laser in the treatment of female pattern hair loss (FPHL).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06926023
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Goldman, Butterwick, Fitzpatrick and Groff trials
Trials by the same sponsor.
- NCT07462533 — Assess Efficacy of a Nanodiamond Periprocedural Skin Care Regimen for Ablative Resurfacing · Phase 2 · not yet recruiting
- NCT07421544 — Assess Injectable Hyaluronic Acid Gel for the Treatment of Volume Loss, Skin Laxity and Fine Lines · Phase 4 · not yet recruiting
- NCT07342413 — Study Comparing Glycerin With 1% Lidocaine and Epinephrine Versus Glycerin With 1% Lidocaine Without Epinephrine for the · Phase 4 · not yet recruiting
- NCT07221461 — Assess Impact of Microdroplet Hyaluronic Acid Filler on Skin Quality in Patients on Glucagon-like Peptide-1 Agonists · Phase 2 · not yet recruiting
- NCT07217743 — Assess Impact of Poly-L-lactic Acid on GLP1 Subjects · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06926023 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Goldman, Butterwick, Fitzpatrick and Groff
- Last refreshed: 16 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06926023.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing